Drug

Diosuxentan clinical trials

studies test it: 3
open now: 2
in phase 3: 1
first study started: 2023

Keep track of what changes. Save the diosuxentan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

SC0062 strength 10mg: 2

Studies by the year they started

2 studies that test it; most in 2023 (1); 1 more planned to start later

Studies that test diosuxentan, by start year
Year	Studies
2023	1
2025	1

By phase

A phase 1/2 study counts in both.

Phase 2: 2
Phase 3: 1

What it is tested for

Each study’s main condition, where its own words name it.

Kidney Diseases: 1
Diabetic Nephropathies: 1
Glomerulonephritis, IGA: 1

Who runs them

Industry 2 · Other 1

Biocity Biopharmaceutics Co., Ltd. (2) · University Medical Center Groningen (1)

Often tested with

Tested in the same studies.

Dapagliflozin (1)

Related medicines

As reviewed, each with the page that says it.

One of Endothelin Receptor Antagonists source

Studies

Open first, then newest update. How each study uses diosuxentan is read from its arms, and is right about nine times in ten.

Testing it · 3

Codes

What other systems call diosuxentan · ClinicalTrials.gg INT017801

UNII (FDA) RJ4QU53ZY3DIOSUXENTANConfirmed FDA, Wikidata
Wikidata Q140528752diosuxentanConfirmed FDA, Wikidata
NCI Thesaurus C224729DiosuxentanOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	RJ4QU53ZY3	DIOSUXENTAN	Confirmed FDA, Wikidata
Wikidata	Q140528752	diosuxentan	Confirmed FDA, Wikidata
NCI Thesaurus	C224729	Diosuxentan	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.